Roche Posts Encouraging Follow-up Data From Phase II CITYSCA

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) reported follow-up efficacy, safety and patient-reported outcomes data from the phase II CITYSCAPE trial, investigating the anti-TIGIT cancer immunotherapy

Related Keywords

Levi Garraway , Head Of Global Product Development , Chief Medical Officer , Global Product Development , Roche , Costs , Ncouraging , Follow , Data , Rom , Hase , Cityscape , Trial ,